Immunohistochemistry-Based Fluorescent Nanoparticle Assay for Determination of Antibody Binding Capacity and Its Correlation with Flow Cytometry Analysis

References

• Gonda, K., M. Watanabe, H. Tada, M. Miyashita, Y. Takahashi-Aoyama, T. Kamei, T. Ishida, S. Usami, H. Hirakawa, Y. Kakugawa, et al. 2017. Quantitative diagnostic imaging of cancer tissues by using phosphor-integrated dots with ultra-high brightness. Scientific Reports 7 (1):7509. doi:10.1038/s41598-017-06534-z.
   PubMedGoogle Scholar
• Guo, Z., H. Tada, N. Kitamura, Y. Hamada, M. Miyashita, N. Harada-Shoji, A. Sato, Y. Hamanaka, K. Tsuboi, N. Harada, et al. 2019. Automated quantification of extranuclear ERα using phosphor-integrated dots for predicting endocrine therapy resistance in HR(+)/HER2(-) breast cancer. Cancers (Basel ) 11 (4):526. doi:10.3390/cancers11040526.
   PubMed Web of Science ®Google Scholar
• Hicks, D. G., B. Buscaglia, H. Goda, L. McMahon, T. Natori, B. Turner, A. Soukiazian, H. Okada, and Y. Nakano. 2018. A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: An analytical and clinical validation study. BMC Cancer 18 (1):1266.
   PubMedGoogle Scholar
• Kontermann, R. E., and U. Brinkmann. 2015. Bispecific antibodies. Drug Discovery Today 20 (7):838–47. doi:10.1016/j.drudis.2015.02.008.
   PubMed Web of Science ®Google Scholar
• Liang, M., M. Schwickart, A. K. Schneider, I. Vainshtein, C. Del Nagro, N. Standifer, and L. K. Roskos. 2016. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry. Part B, Clinical Cytometry 90 (2):117–27. doi:10.1002/cyto.b.21259.
   PubMed Web of Science ®Google Scholar
• Magaki, S., S. A. Hojat, B. Wei, A. So, and W. H. Yong. 2019. An introduction to the performance of immunohistochemistry. Methods in Molecular Biology 1897:289–98.
   PubMedGoogle Scholar
• O'Hurley, G., E. Sjostedt, A. Rahman, B. Li, C. Kampf, F. Ponten, W. M. Gallagher, and C. Lindskog. 2014. Garbage in, garbage out: A critical evaluation of strategies used for validation of immunohistochemical biomarkers. Molecular Oncology 8 (4):783–98. doi:10.1016/j.molonc.2014.03.008.
   PubMed Web of Science ®Google Scholar
• Sharma, P., and D. M. Kranz. 2016. Recent advances in T-cell engineering for use in immunotherapy. F1000Research 5:2344. doi:10.12688/f1000research.9073.1.
   Google Scholar
• Staflin, K., C. L. Zuch de Zafra, L. K. Schutt, V. Clark, F. Zhong, M. Hristopoulos, R. Clark, J. Li, M. Mathieu, X. Chen, et al. 2020. Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody. JCI Insight 5 (7):e133757. doi:10.1172/jci.insight.133757.
   PubMed Web of Science ®Google Scholar
• Sternebring, O., L. Alifrangis, T. F. Christensen, H. Ji, A. C. Hegelund, and C. M. Hogerkorp. 2016. A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development. Cytometry. Part B, Clinical Cytometry 90 (2):220–9. doi:10.1002/cyto.b.21277.
   PubMed Web of Science ®Google Scholar
• Stewart, J. J., C. L. Green, N. Jones, M. Liang, Y. Xu, D. E. Wilkins, M. Moulard, K. Czechowska, D. Lanham, T. W. McCloskey, et al. 2016. Role of receptor occupancy assays by flow cytometry in drug development. Cytometry. Part B, Clinical Cytometry 90 (2):110–6. doi:10.1002/cyto.b.21355.
   PubMed Web of Science ®Google Scholar
• Suzuki, M., S. Yagishita, K. Sugihara, Y. Ogitani, T. Nishikawa, M. Ohuchi, T. Teishikata, T. Jikoh, Y. Yatabe, K. Yonemori, et al. 2021. Visualization of intratumor pharmacokinetics of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2 heterogeneous model using phosphor-integrated dots imaging analysis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 27 (14):3970–9. doi:10.1158/1078-0432.CCR-21-0397.
   PubMed Web of Science ®Google Scholar
• Tanaka, S., K. Takizawa, and F. Nakamura. 2022. One-step visualization of natural cell activities in non-labeled living spheroids. Scientific Reports 12 (1):1500. doi:10.1038/s41598-022-05347-z.
   PubMed Web of Science ®Google Scholar
• Tatsumi, A., K. Morichika, J. Krueger, and H. Yokota. 2022. High-sensitivity immunohistochemistry method using a combination of fluorescent nanoparticles and tyramide linker. Analytical Letters 56 (7):1–10. doi:10.1080/00032719.2022.2123498.
   Web of Science ®Google Scholar
• Wang, H. Z., H. Y. Wang, R. Q. Liang, and K. C. Ruan. 2004. Detection of tumor marker CA125 in ovarian carcinoma using quantum dots. Acta Biochimica et Biophysica Sinica 36 (10):681–6. doi:10.1093/abbs/36.10.681.
   PubMed Web of Science ®Google Scholar
• Wuellner, U., K. Klupsch, F. Buller, I. Attinger-Toller, R. Santimaria, I. Zbinden, P. Henne, D. Grabulovski, J. Bertschinger, and S. Brack. 2015. Bispecific CD3/HER2 targeting FynomAb induces redirected T cell-mediated cytolysis with high potency and enhanced tumor selectivity. Antibodies 4 (4):426–40. doi:10.3390/antib4040426.
   Google Scholar